<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02181985</url>
  </required_header>
  <id_info>
    <org_study_id>1123.10</org_study_id>
    <nct_id>NCT02181985</nct_id>
  </id_info>
  <brief_title>Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)</brief_title>
  <acronym>ASSENT 3</acronym>
  <official_title>A Phase IIIb, Randomised, Open Label Trial With 3 Parallel Groups: Full Dose TNK-tPA Together With Heparin Sodium, Full Dose TNK-tPA Together With Enoxaparin, and Half Dose TNK-tPA Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction: ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of ASSENT 3 was to evaluate the safety and efficacy of full dose tenecteplase
      with heparin sodium (group A), full dose tenecteplase combined with enoxaparin (group B) and
      half dose tenecteplase combined with abciximab and heparin sodium (group C).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <primary_completion_date type="Actual">April 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia or in-hospital intracranial hemorrhage (ICH) or in-hospital major bleedings (other than ICH)</measure>
    <time_frame>Up to 30 days after discharge from hospital</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoints: 30-day mortality or in-hospital reinfarction or in-hospital refractory ischemia</measure>
    <time_frame>Up to 30 days after discharge from hospital</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5989</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Full dose TNK-tPA</intervention_name>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Half dose TNK-tPA</intervention_name>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <arm_group_label>TNK-tPA + heparin</arm_group_label>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <arm_group_label>TNK-tPA + enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abciximab</intervention_name>
    <arm_group_label>TNK-tPA + abciximab + heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Onset of symptoms of AMI within six hours prior to randomisation

          -  A twelve-lead electrocardiogram with one of the following: ST-segment elevation ≥ 0.1
             millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous
             precordial leads indicative of AMI, or left bundle-branch block

          -  Age ≥ 18

          -  Informed consent received

        Exclusion Criteria:

          -  Hypertension defined as blood pressure &gt; 180/110 mm Hg (systolic BP &gt;180 mm Hg and/or
             diastolic BP &gt;110 mm Hg) on repeated measurements during current admission prior to
             randomization

          -  Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the
             preceding 7 days

          -  Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months

          -  Any minor head trauma and any other trauma occurring after onset of the current
             myocardial infarction

          -  Any known history of stroke or transient ischemic attack or dementia

          -  Any known structural damage of the central nervous system

          -  Prolonged cardiopulmonary resuscitation (&gt;10 minutes) in the previous two weeks

          -  Current oral anticoagulation

          -  Standard unfractionated heparin (heparin sodium) &gt;5000 IU or a subcutaneous dose
             within 6 hours of randomization of a therapeutic dose of any low molecular weight
             heparin

          -  Known thrombocytopenia (prior platelet count below 100000 cells/μl (100 x10**9/l))

          -  Known renal insufficiency (prior S-creatinine &gt;2.5 mg% (&gt;220 μmol/l) for men and &gt;2.0
             mg% (&gt;175 μmol/l)) for women

          -  Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing
             potential must have a negative pregnancy test, or use a medically accepted method of
             birth control

          -  Treatment with an investigational drug under another study protocol in the past 7 days

          -  Previous enrollment in this study

          -  Known sensitivity to TNK-tPA, tPA, abciximab, heparin or low molecular weight heparin

          -  Any other condition that the investigator feels would place the patient at increased
             risk if the investigational therapy is initiated

          -  Inability to follow protocol and comply with follow-up requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 2, 2014</study_first_submitted>
  <study_first_submitted_qc>July 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Abciximab</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

